Do you think it is realistic to see MNTA's Enbrel ANDA [assuming there is one] approval and launch before Jan 2014?
No—that’s totally unrealistic, IMO. Also, such an application would not be an ANDA but rather a 351(k) submission.
Some dates of 2016-2017 were bandied around in [GS] the conference call ...Can somebody put that in context ? Was CW saying the 1st bio-similar in the US could get approved/launched as early/as late as 2016?
I didn’t catch that reference, so I would have to listen to the webcast again to answer your question. (If anyone reading this knows, please post.)
Enbrel sales were approx $1billion in 2010.
You’re off by a factor of seven (#msg-59851976)! In the US alone, Enbrel sells at an annualized rate of $3.5B.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.